

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Comparison of the effect of misoprostol and letrozole in the first-trimester abortion of patients referring to Ganjavian Hospital in Dezful in 1400

Protocol summary

Study aim

A comparative study of the therapeutic effects of two different letrozole and misoprostol regimens in the first-trimester abortion

Design

single-blind

Settings and conduct

Proper counseling will be done and written informed consent will be obtained before starting the treatment regimen. Group A patients will receive 2 misoprostol tablets orally and two vaginally in the posterior fornix of the vagina (800µg) and this dose will be repeated up to 3 times every 4 hours as needed. In groups B and c, 10 mg of oral letrozole (2.5 mg) was administered twice daily for 3 and 5 days, respectively, on the last day of letrozole administration, patients will be hospitalized and receive vaginal misoprostol 400 µg of misoprostol vaginally , 400 µg of misoprostol will be used sublingually in both groups.

Participants/Inclusion and exclusion criteria

Inclusion criteria: hemoglobin level more than 10 gr/liter , diastolic pressure less than 95 mm Hg, gestational age less than 14 weeks Exclusion criteria: use of drugs in the last three months for abortion, pregnancy pruritis , adrenal disorders, porphyria, steroid-dependent cancer, acute or chronic liver disease , thromboembolism, history of chronic lung diseases , known allergy to letrozole or misoprostol, lactation, multifetal pregnancy, more than two previous cesarean sections, history of uterine surgery and myomectomy, contraindications to misoprostol and letrozole, intrauterine devices, uncontrolled seizures, coagulation disorder or use Anticoagulants, Active liver disease, Cardiovascular disease, Glucocorticoid use

Intervention groups

In this interventional study, 75 pregnant women under 14 weeks of gestational age who are candidates for

therapeutic abortion will be selected and divided into three groups using the block randomization method (n=25 in each group).

Main outcome variables

Medical abortion

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200217046521N1**

Registration date: **2021-10-03, 1400/07/11**

Registration timing: **registered_while_recruiting**

Last update: **2021-10-03, 1400/07/11**

Update count: **0**

Registration date

2021-10-03, 1400/07/11

Registrant information

Name

Vahid Kheirandish

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 61 4223 0453

Email address

vahid.kheirandish40@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-09-21, 1400/06/30

Expected recruitment end date

2023-03-21, 1402/01/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of the effect of misoprostol and letrozole in the first-trimester abortion of patients referring to Ganjavian Hospital in Dezful in 1400

Public title

Evaluation of the effects of misoprostol and letrozole in therapeutic abortion

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Hemoglobin level greater than 10 gr / l Diastolic pressure less than 95 mmhg Serum hcg level less than 3000 iu / l Gestational age less than 14 weeks

Exclusion criteria:

Use of abortion drugs in the last three months itching during pregnancy Existence of adrenal disorders Porphyria, steroid-related cancer, acute or chronic liver disease or thromboembolism History of chronic lung diseases such as asthma, bronchitis, bronchiectasis known allergy to letrozole or misoprostol Breast feeding Multipfetal pregnancy More than two previous cesarean sections uterine surgery and myomectomy contraindications to the letrozol and mosoprostol Existence of intrauterine devices (IUD) Uncontrolled seizures Coagulation disorder or use of anticoagulants Active liver disease, cardiovascular disease Adrenal disease Consumption of glucocorticoids

AgeFrom **18 years** old**Gender**

Female

Phase

3

Groups that have been masked

- Participant

Sample sizeTarget sample size: **75****Randomization (investigator's opinion)**

Randomized

Randomization description

In order to randomize the samples and also to balance the study groups, patients will be divided into 3 groups by the block randomization method by the researcher. In this method, the researcher will place each patient in one of 3 groups: A (misoprostol) or B (3-day letrozole + misoprostol) or C (5-day letrozole + misoprostol). Blocking in the form of six blocks One will be done and 8 blocks will be formed according to the number of sample population. We predict all possible arrangements of groups, for example, the first block will be AABBC and the next block. For example, it will be predicted as CAB CAB and the rest of the blocks will be defined in the

same way. Due to the large number of blocks, block randomization software will be used and then 8 blocks will be selected randomly with the help of a table of random numbers. Individuals will also be randomly selected and placed in blocks. Eventually, the sample size will be the same in the groups and 25 patients will be in each group A, B and C.

Blinding (investigator's opinion)

Single blinded

Blinding description

Participants in the study will be placed in three ABC groups by the researcher. Patient randomization will be done by the researcher in blocks and after coding, the study and control groups will enter the data for analysis in the software The group treated with misoprostol with code A, the group treated with letrozole 3 days + misoprostol with code B and the group treated with letrozole 5 days + misoprostol with code C will be coded. It should be noted that the participants in the study do not know about the treatment and medication regimen performed for them, but researchers and statistical analysts know what diet each participant received.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committees of Dezful University of Medical Sciences

Street address

Azadegan Boulevard, Daneshjoo Square

City

Dezful

Province

Khuzestan

Postal code

6461665145

Approval date

2020-10-31, 1399/08/10

Ethics committee reference number

IR.DUMS.REC.1399.047

Health conditions studied**1****Description of health condition studied**

medical abortion

ICD-10 code

000-008

ICD-10 code description

Medical abortion

Primary outcomes

1

Description

Fetus abortion

Timepoint

Before and after abortion

Method of measurement

Eight hours after the intervention, and every twenty-four hours up to three days if the abortion doesn't occur

Secondary outcomes

empty

Intervention groups

1

Description

Control group: Group A patients in whom abortion will be performed with vaginal and oral misoprostol are given two 200 µg misoprostol tablets orally (sublingually) and two vaginally in the posterior vaginal fornix (800µ totally) and then this amount will be repeated every 4 hours p to 3 days as needed. Intervention group: In group B, where abortion is performed vaginally with oral letrozole and misoprostol, 10 mg of oral letrozole is given to the patient twice daily for 3 days (2 tablets of 2.5 mg each) followed by 400 mg. Misoprostol will be used vaginally in the posterior fornix and 4g400 misoprostol will be used sublingually.

Category

Treatment - Drugs

2

Description

Intervention group: In group B, abortion treatment with oral letrozole and misoprostol will be performed vaginally, 10 mg oral letrozole for 3 days for the patient in two meals a day (2 tablets of 2.5 mg each meal) is prescribed on an outpatient basis and then in On the last day of taking letrozole, 400 mg of misoprostol will be administered vaginally in the posterior fornix and 400 mg of misoprostol will be used sublingually.

Category

Treatment - Drugs

3

Description

Intervention group: In group B, abortion treatment with oral letrozole and misoprostol will be performed vaginally, 10 mg oral letrozole for 5 days for the patient in two meals a day (2 tablets of 2.5 mg each meal) is prescribed on an outpatient basis and then in On the last day of taking letrozole, 400 mg of misoprostol will be administered vaginally in the posterior fornix and 400

mg of misoprostol will be used sublingually.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Ganjavian Hospital, Dezful

Full name of responsible person

Sima Janati

Street address

Ganjavian Hospital, Ganjavian Hospital, Dezful - Andymeshk Road, Beasat Blvd. Dezful

City

Dezful

Province

Khuzestan

Postal code

6461643981

Phone

+98 61 4242 2047

Email

sjanati@ymail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Dezfoul University of Medical Sciences

Full name of responsible person

Meysam Mard-Soltani

Street address

Dezfoul University of Medical Sciences, Daneshjoo Blvd, Azadegan St.

City

Dezful

Province

Khuzestan

Postal code

6461665145

Phone

+98 61 4242 9735

Email

mardsoltani.m@dums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Dezfoul University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Dezful University of Medical Sciences

Full name of responsible person

vahid.kheirandish

Position

Non-faculty, anesthesiologist

Latest degree

Bachelor

Other areas of specialty/work

Anesthesiology

Street address

No. 646, Shahid Dastgheib alley, Sahel street ,Shariati crossroads

City

Dezful

Province

Khouzestan

Postal code

6461865967

Phone

+98 71 4452 7941

Fax**Email**

vahid.kheirandish40@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Dezful University of Medical Sciences

Full name of responsible person

dr. Sima janati

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

infertility

Street address

Department of Obstetrics and Gynecology, Ganjavian Hospital, Dezful-Andymeshk Road

City

Dezfull

Province

Khouzestan

Postal code

6461643981

Phone

+98 42429781

Email

sjanati@ymail.com

Person responsible for updating data**Contact****Name of organization / entity**

Dezful University of Medical Sciences

Full name of responsible person

Dr.sima janati

Position

Assistant professor

Latest degree

Subspecialist

Other areas of specialty/work

infertility

Street address

Department of Obstetrics and Gynecology, Ganjavian hospital,dezful - andimeshk road

City

Dezful

Province

Khouzestan

Postal code

6461643981

Phone

+98 42429781

Email

sjanati@ymail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

All documents and statistical tests and the results will be mentioned in the form of graphs and tables in the final article

When the data will become available and for how long

Access period starts 6 months after the results are published

To whom data/document is available

By publishing the article, all people who have access to the Internet can access the results

Under which criteria data/document could be used

In order to develop the science related to abortion treatment and facilitate the process with the least complications, everyone will be able to access

From where data/document is obtainable

It will be available on Google Scholar by mentioning the names of the authors and keywords

What processes are involved for a request to access data/document

nothing
Comments